<a href="https://laohu8.com/S/CTMX">CytomX</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter 2025 financial results
CytomX Therapeutics Inc. reported cash, cash equivalents and investments of $143.6 million at the end of the third quarter of 2025, with an expected cash runway through the second quarter of 2027. Total operating expenses for the third quarter of 2025 were $21.7 million, down from $29.3 million in the same period of 2024. Research and development expenses were $15.3 million, a decrease of $6.1 million compared to the prior year, primarily due to reduced spending on the CX-904 program, restructuring, and lower CX-2051 manufacturing costs, partially offset by higher CX-2051 clinical expenses. General and administrative expenses were $6.4 million, down $1.5 million year-over-year, mainly due to lower personnel, patent, and legal costs. Key business developments included continued progress in the CX-2051 Phase 1 trial, with a data update expected in the first quarter of 2026, and ongoing research collaborations focused on bispecific immunotherapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570752-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.